In the 10 years since the discovery of lysine‐specific demethylase 1 (LSD1), this epigenetic
eraser has emerged as an important target of interest in oncology. More specifically …

Purpose Secondary and therapy-related acute myeloid leukemia (sAML and tAML,
respectively) remain therapeutic challenges. Still, it is unclear whether their inferior outcome …

Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical
trials and thus, population‐based studies are crucial for its accurate characterization. In this …

Purpose Both presence of minimal residual disease (MRD) and achievement of complete
remission (CR) with incomplete platelet recovery (CRp) rather than CR after induction …

Acute myeloid leukemia (AML) is a heterogeneous disease in its clinical presentation,
response to therapy, and overall prognosis. For decades, pretreatment karyotype evaluation …

Minimal residual disease (MRD) is associated with adverse outcome in acute myeloid
leukemia (AML) after myeloablative (MA) hematopoietic cell transplantation (HCT). We …

Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We
used area under receiver-operating characteristic curves (AUCs) to quantify our ability to …

The strategy of enzymatic degradation of amino acids to deprive malignant cells of important
nutrients is an established component of induction therapy of acute lymphoblastic leukemia …

In this study we used a next generation sequencing-based approach to profile gene
mutations in therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid …

We assessed the frequency and clinicopathologic significance of 19 genes currently
identified as significantly mutated in myeloid neoplasms, RUNX1, ASXL1, TET2, CEBPA …